Recent

% | $
Quotes you view appear here for quick access.

Capital One Financial Corporation Message Board

gothzillaman 12 posts  |  Last Activity: Aug 23, 2015 8:21 AM Member since: May 4, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    LINDA, NWBO , ALL INVOLVED WITH THE TRIALS

    by robynkaygerkin Aug 22, 2015 4:48 PM
    gothzillaman gothzillaman Aug 23, 2015 8:21 AM Flag

    Nice Fellow, research the dangers of liver damage from Tylenol especially after ingestion of alcohol drinks. Can be fatal in some cases.

  • Reply to

    SRNE DEAL IN CHINA NEWS

    by a_sky_pilot Aug 19, 2015 9:58 AM
    gothzillaman gothzillaman Aug 19, 2015 3:25 PM Flag

    FINALLY....a chance to steal CHINESE technology!!!

  • gothzillaman gothzillaman Aug 16, 2015 1:18 AM Flag

    When I made this post on June 12, the Yahoo earnings estimates for 2015 were $5.19.

    "Am new to this stock, so not an expert by any means....but the difference between azelfage P/E of 50 and the Yahoo estimates of "earnings" $5.19 and $7.21 for 2015/16 comes from azelfage using GAAP earnings and AMAG and Yahoo using EBITDA minus cash interest costs of approx $30MM per year."

    Eight weeks later the 2015 earnings are being "raised" to $1.42? That is clear evidence that the Analysts don't know how to model the short term earnings for EGRX. Be careful on putting too much stock in Yahoo earnings estimates for a startup company.

    I like the EGRX overall story for 2016 and low number of shares. Been around long enough to be suspicious of the magical $7 per share earnings for "next year".

    I entered orders to sell Aug 90 and 95 puts to re-enter a long position. Thank goodness my ask prices were too high at the moment, and I soon cancelled to wait until after earnings. Waiting one week has witnessed a decline from $105 head fake after earnings to mid-60"s. Certainly the risk now is much lower than at $95.

    The big funds with tens of billions of dollars are selling biotech and pharma at the moment. We may know why, or why they were idiots, in 3-8 months. EGRX is almost sure to provide a wild ride for its stock investors and traders.

  • Have no position here, but am interested in possibly buying some shares.

    There apparently is one analyst projecting 2016 revenues at $393MM. Does anyone have a plausible scenario under which that could happen? Does not seem possible, given the NDA for BPH is not even filed yet.

    At a share price of $2.53, the out months 2.50 puts have a higher price than the calls. I am tempted to sell some puts against cash, in addition to having some shares long. Anybody have any thoughts on why puts have higher premium at this time, given that put potential is capped at zero and call potential could be boundless?

  • gothzillaman by gothzillaman Aug 12, 2015 2:34 AM Flag

    My guess is that Eagle got hosed on all of these changes. Why don't they say "the royalty rate was changed from X to Y"...instead of hiding the facts?

    Robert One, LLC Amendment to Development and Licensing Agreement
    On August 5, 2015, Eagle Pharmaceuticals, Inc., or the Company, entered into Amendment No. 2 to Development and Licensing Agreement (the "Second Amendment") with Robert One, LLC ("Robert One") to revise the "Royalty Rate" as defined in the Development and Licensing Agreement, dated as of February 13, 2009, as amended (the "Robert Development and Licensing Agreement").

    The Second Amendment revises the definition of "Royalty Rate" to mean: (i) 50% with respect to a 505(b)(2) application; (ii) 30% with respect to an ANDA application; and (iii) 25% with respect to the Pemetrexed parenteral formulation.

    SciDose LLC Amendment to Development and Licensing Agreement

    On August 5, 2015, the Company entered into Amendment No. 4 to Development and Licensing Agreement (the "Fourth Amendment") with SciDose LLC ("SciDose") to waive certain claims against SciDose and to revise the "Royalty Rate" as defined in the Development and Licensing Agreement, dated as of June 12, 2007, as amended (the "SciDose Development and Licensing Agreement"). The SciDose Development and Licensing Agreement is described in the Company's Registration Statement on Form S-1, filed with the Securities and Exchange Commission on December 20, 2013, and attached thereto as Exhibit 10.11(b).

    The Fourth Amendment revises the definition of "Royalty Rate" to mean: (i) 15% with respect to the Eagle Bivalirudin Product; (ii) 50% with respect to any Product that is subject to

  • Reply to

    bankruptcy immernent for all shales

    by ramstrung Jul 31, 2015 5:25 PM
    gothzillaman gothzillaman Aug 1, 2015 5:12 AM Flag

    Please explain the word "immernent".

    I am writing a thesis about the decline of America.

  • Reply to

    This will go down again.. I will not wondering..

    by django.asyl Jul 31, 2015 11:58 AM
    gothzillaman gothzillaman Aug 1, 2015 3:42 AM Flag

    Can you explain the phrase "I will not wondering".

    Watching the decline of a once-great civilization is difficult to bear.

  • Reply to

    Read the company's lips!

    by itsahorserace Jul 18, 2015 2:56 PM
    gothzillaman gothzillaman Jul 19, 2015 12:49 AM Flag

    I would be much more impressed if the message was delivered by a scantily clothed Hannah, walking beside the Synergy spokesman who would be on all-fours, along a Caribbean white beach.

  • Can you give us one last bwaahaaahaabwaaa as an obnoxious short and explain why you are stupid enough to claim that an enterprise software stock earning $2 per share will follow the same trajectory as a failed solar panel company? Bwaahaahaaa.

    Bwaaahhaahhaaa......

  • Reply to

    RBC Capital - $97 Price Target

    by promocuda Jun 22, 2015 4:23 PM
    gothzillaman gothzillaman Jun 22, 2015 10:49 PM Flag

    I am assuming that $97 was a 24-hour price target.......

    Wonder what they are thinking longer term?

  • Reply to

    AMAG est EPS

    by soflaturtle Jun 13, 2015 2:58 PM
    gothzillaman gothzillaman Jun 20, 2015 12:44 AM Flag

    Soflaturtle, in all due respect, from the content and tone of your post it would seem that you are best suited to writing into a private diary and not engaging with others. You may benefit from curling up inside your protective shell and escaping the scourges of the outside world. As you correctly stated, the open exchange of ideas from others can be confounding, and in your case, enraging. In some cases, it is best to just walk away.

  • gothzillaman by gothzillaman Jun 12, 2015 4:50 AM Flag

    Am new to this stock, so not an expert by any means....but the difference between azelfage P/E of 50 and the Yahoo estimates of "earnings" $5.19 and $7.21 for 2015/16 comes from azelfage using GAAP earnings and AMAG and Yahoo using EBITDA minus cash interest costs of approx $30MM per year. The big $ adjustment is for the $50MM per year of non-cash depreciation of intangible assets (I assume goodwill from the Makena purchase, and other purchases).

    Looks to me like the current market is OK with the net cash flow for valuation. Azelfage states that Mcguff Pharma is working on a generic Makena, and have been since 2009. Assuming that is true, seems like it must be either a low priority or difficult to not have completed something so "easy" in 6 years.

COF
77.32-0.04(-0.05%)Aug 28 4:00 PMEDT